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Objective: Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR)
C677T mutations are considered risk factors for venous thromboembolism. It remains to be characterized whether the
presence of these relatively common mutations poses a risk for peripheral arterial disease (PAD). Therefore, we intended
to test, by conducting a case-control study, the hypothesis that PAD was associated with an increased prevalence of factor
V G1691A, prothrombin G20210A, and MTHFR C677T mutations.
Methods: The study comprised 433 patients admitted for inpatient diagnostics and treatment of PAD in patients with
chronic limb ischemia. Patients with acute ischemia or malignancy were excluded. A total of 433 control subjects matched
to the patients with PAD in a 1:1 design by sex, age (2 years), and diabetes mellitus status were recruited. Factor V
G1691A, prothrombin G20210A, and MTHFR C677T genotypes were assessed by polymerase chain reaction.
Results: For the factor V G1691A polymorphism, the genotype frequencies in PAD patients were 92.8% GG (normal
homozygotes  wild type) and 7.2% GA (mutant heterozygotes), and in control subjects they were 94.0% GG and 6.0%
GA (2 test; P  .493). The distribution of the prothrombin G20210A genotypes was 96.3% GG (normal homozygotes
 wild type) and 3.7% GA (mutant heterozygotes) in PAD patients and was 97.2% GG and 2.8% GA in control subjects
(2 test; P  .442). Genotype frequencies for the MTHFR C677T polymorphism were 47.8% CC (normal homozygotes
 wild type), 43.4% CT (mutant heterozygotes), and 8.8% TT (mutant homozygotes) in PAD patients, compared with
47.1% CC, 44.1% CT, and 8.8% TT in control subjects (2 test; P  .977). Accordingly, as determined by logistic
regression analysis, no significant odds ratios for heterozygous or homozygous genotypes of the three polymorphisms
could be observed.
Conclusions: PAD was not associated with an increased prevalence of factor V G1691A, prothrombin G20210A, and
MTHFR C677T mutations in the population studied. Thus, there is no indication that of one of these mutations may be
a risk factor for chronic limb ischemia. However, the role of these mutations in acute limb ischemia remains to be clarified.
(J Vasc Surg 2005;41:808-15.)Atherosclerotic peripheral arterial disease (PAD) is a
progressive condition characterized by arterial stenoses and
occlusions in the peripheral arterial bed of the lower limbs;
it can be symptomatic or asymptomatic. Symptomatic PAD
ranges in severity from intermittent claudication to critical
limb ischemia.1 In the population older than 55 years, PAD
is an indicator of systemic atherosclerotic disease. Regard-
less of whether symptoms are evident, patients with PAD
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808have an increased risk of subsequent myocardial infarction
and stroke and are six times more likely to die within 10
years than are patients without PAD.2 Diabetes mellitus
and smoking are the strongest risk factors for PAD.1,2
Other well-known risk factors are advanced age, male sex,
arterial hypertension, dyslipidemia, prior myocardial infarc-
tion, history of stroke, and history of transient ischemic
attack.2,3 Emerging risk factors for PAD include increased
levels of high-sensitivity C-reactive protein (CRP), total
homocysteine (tHcy), and 8-iso-prostaglandin F2 as an
indicator of oxidative stress.3-5 Thrombophilic conditions,
such as factor V G1691A (Leiden), prothrombin (factor II)
G20210A, and methylenetetrahydrofolate reductase
(MTHFR) C677T mutations, have been investigated, but
current evidence does not unequivocally support the hy-
pothesis that one of these mutations may be a risk factor for
PAD.6-15
Activated protein C resistance has been reported to be
the most common cause of familial thrombophilia.16 In
most of these cases, the activated protein C resistance is the
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known as factor V Leiden. This defect, which is inherited
autosomal dominant, yields factor V much more resistant
to the proteolytic degradation by activated protein C.16
This phenomenon results in a hypercoagulable state and is
seen in approximately 5% of white populations, in up to
50% in selected thrombophilic families, and in 10% of
unselected venous thrombosis patients.16 The risk for ve-
nous thrombosis is also increased in patients who have a
mutation in the prothrombin gene (G20210A).16 This
mutation results in increased levels of prothrombin due to
increased prothrombin synthesis and is associated with a
threefold increase in the risk for venous thrombosis. Ap-
proximately 5% to 10% of patients with venous thrombosis
and approximately 15% of patients being investigated for
thrombophilia will harbor this disorder; up to 4% of indi-
viduals in the general population will test positive for this
defect.16 The most common hereditary abnormality asso-
ciated with hyperhomocysteinemia is a variant that makes
the MTHFR gene product thermolabile, thus resulting in
functional MTHFR deficiency. The MTHFR C677T mu-
tation is common; in some populations, up to 40% to 50%
of unselected patients are heterozygous for this mutation,
and approximately 10% to 15% are homozygous.16 This
mutation is not associated with hyperhomocysteinemia in
heterozygous patients and is associated with increased tHcy
concentrations only in homozygous patients in the pres-
ence of coexisting deficiencies of folate, vitamin B12, or
vitamin B6.
16 Certain studies have suggested that increased
homocysteine levels roughly double the incidence of ve-
nous thrombosis.17 Overall, however, there seems to be a
weak positive association.18
Factor V G1691A, prothrombin G20210A, and prob-
ably also MTHFR C677T mutations are considered risk
factors for venous thromboembolism. However, there is
controversy about the role of these mutations in arterial
thrombotic disease and atherosclerosis.19 Because of the
small number of published studies, it remains even less well
characterized whether the presence of these relatively com-
mon mutations poses a risk for PAD. Four studies describ-
ing a possible role of the factor V G1691A and/or pro-
thrombin G20210A polymorphisms as risk factors for PAD
revealed conflicting results.6-9 Six studies investigating the
association of PAD with hyperhomocysteinemia and the
MTHFR C677T polymorphism also do not unequivocally
support their hypothesized role as independent risk fac-
tors.10-15 In addition, most of the cited studies on PAD
were investigating small populations and had several limi-
tations related to the method of matching cases and con-
trols or related to the spectrum or delineation of cases and
controls.19 Therefore, we intended to address the associa-
tion of PAD with factor V G1691A, prothrombin
G20210A, and MTHFR C677T mutations by conducting
a large case-control study with a well-defined study popu-
lation and with the controls matched to patients with PAD
in a 1:1 design by age, sex, and diabetes mellitus status.
Using this study design, we tested the hypothesis that PADwas related to an increased prevalence of one of the three
mutations.
METHODS
Study population. The Linz Peripheral Arterial Dis-
ease (LIPAD) study was performed from April 2000 to
April 2002 at the St. John of God Hospital, Department of
Surgery, Linz, Austria. Of the patients admitted for inpa-
tient evaluation of suspected or definite PAD during the
given time interval, all patients with chronic atherosclerotic
occlusive disease of the lower extremities associated with
typical symptoms—such as claudication or leg pain on
exertion, rest pain, or minor or major tissue loss—were
included into this study on the basis of the final clinical
diagnosis established by the attending vascular surgeons.
The diagnosis was verified by interview, physical examina-
tion, noninvasive techniques, and angiography, as detailed
below. All cases with acute ischemia (ie, peripheral arterial
thrombosis of a native artery or popliteal artery aneurysm or
acutely thrombosed peripheral bypass grafts) were ex-
cluded. Further exclusion criteria were PAD caused by
nonatherosclerotic causes (cardioembolic disease, throm-
boangiitis obliterans, vasculitis, or congenital or metabolic
vascular disease) and the history or presence of any malig-
nancy. The study population comprised 487 consecutive
subjects with symptomatic chronic limb ischemia. This
series of white patients included 318 nondiabetic and 169
diabetic subjects. Of the 318 nondiabetic patients with
PAD, 216 were younger than 75 years of age, and 102 were
75 years of age or older; of the 169 diabetic patients with
PAD, 115 were younger than 75 years of age, and 54 were
75 years of age or older. The LIPAD study was designed to
evaluate possible phenotypic and genotypic risk factors for
PAD by using a case-control design and to determine the
predictive value of risk factors on the long-term outcome of
patients with symptomatic PAD. The study protocol was
approved by the local ethics committee in accordance with
the Declaration of Helsinki, and all study participants gave
informed consent.
All study subjects (ie, cases and controls) underwent
evaluation for the presence of risk factors for atherosclerosis
and comorbid conditions, as recommended.20 Coronary
artery disease (CAD) was defined as remote myocardial
infarction by history, occult myocardial infarction by elec-
trocardiography, previous coronary bypass surgery or per-
cutaneous transluminal coronary angioplasty, and stable or
unstable angina and acute coronary syndrome (cardiac
troponin positive or negative). Cerebrovascular disease
(CVD) was defined as transient or temporary stroke, com-
pleted stroke with permanent neurologic deficit, or acute
stroke. Arterial hypertension was defined as the use of any
antihypertensive medication, systolic blood pressure of 145
mmHg or higher, or diastolic blood pressure of 90mmHg
or higher. Diabetes mellitus was defined as the use of any
glucose-lowering medication or as fasting blood glucose
levels of 126 mg/dL or higher. Smoking was classified
according to recommended standards.20 The subjects’
height and weight were routinely measured when they were
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the ratio of weight to height squared.
In patients with symptomatic PAD and control sub-
jects, Doppler segmental blood pressure of the lower limbs,
including continuous-wave spectral analysis and resting
ankle-brachial index (ABI) measurements, as well as color
duplex ultrasound scanning of the carotid bifurcation and
the internal carotid artery, were performed as previously
described.21,22 In addition to these measurements, intra-
arterial aortofemoral angiography was performed in all
patients to confirm the presence of PAD and to determine
the location and extent of wall changes.
Control subjects matched to the patients with PAD in a
1:1 design by sex, age (2 years), and diabetes mellitus
status were recruited for all nondiabetic patients (n 319)
and for diabetic patients younger than 75 years of age (n
115). All control subjects were patients in our hospital and
fulfilled the following criteria: no clinical indication of PAD
by history and physical examination; systolic brachial blood
pressure equal to or less than the blood pressure in of each
of the right and left anterior tibial and posterior tibial
arteries (ie, ABI 1.0); no pathologic pattern of pulse
waves in lower limbs by continuous-wave spectral analysis;
no CAD; no CVD; no previous vascular surgery or stenting
of the internal carotid arteries; no stenosis of the internal
carotid artery greater than 50% by color duplex ultrasound
scans; no history of venous thromboembolism; and no
history or presence of any malignancy. All control subjects
were generally in good health and were admitted for treat-
ment of minor health problems, such as cataract surgery,
vertebragenic pain, or nonvascular surgery (eg, herniotomy
or varicose vein extirpation).
Biochemical analyses. Blood was collected at veni-
puncture in Vacuette polyethylene terephthalate glycol clot
activator tubes (Greiner Bio-One, Kremsmuenster, Aus-
tria) after the patient had fasted overnight. Creatinine,
fasting glucose, glycohemoglobin A1c, total cholesterol,
and triglycerides were analyzed with standard assays on a
COBAS Integra analyzer (Roche Diagnostics, Mannheim,
Germany). For determination of high-density lipoprotein
cholesterol and low-density lipoprotein cholesterol, quan-
titative electrophoresis with enzymatic staining (Helena
BioSciences, Europe, Sunderland, UK) was used. Total
Hcy, folate, and vitamin B12 assays were performed on an
AxSYM analyzer (Abbott Diagnostics, Abbott Park, Ill).
The concentration of CRP was measured by a high-sensi-
tivity assay (N High Sensitivity CRP) on a BN ProSpec
analyzer (Dade Behring, Marburg, Germany) with polysty-
rene particles coated with monoclonal mouse antibodies to
CRP.
Genotyping. Genomic DNA was isolated from buffy
coat prepared from ethylenediaminetetraacetic acid whole-
blood samples by using the commercially available Purgene
DNA isolation kit (Gentra Systems, Minneapolis, Minn)
and was frozen at 80°C until further assessment. Real-
time multiplex fluorescence polymerase chain reaction
(PCR) was performed for simultaneous detection of factor
V G1691A and prothrombin G20210A polymorphisms byusing primer sequences described previously.23,24 The two
probes targeting several gene-specific amplicons were la-
beled with two different reporter dyes to achieve multiplex
genotyping in a single glass capillary. For the MTHFR
C677T polymorphism, a separate PCR was performed that
used slightly modified primers and probes of validated
methods.25,26 PCR reactions were performed according to
standardized procedures on a LightCycler (Roche Diag-
nostics). In each run, an H2O control and known homozy-
gotes and heterozygotes for the tested polymorphisms were
included to check for unspecific reactions and to confirm
correct genotyping, respectively.
Statistical methods. Statistical analysis was performed
with the SPSS version 10.0 software (SPSS Inc, Chicago,
Ill). Dichotomous variables are given as prevalence in num-
ber, and continuous data are expressed as median (25th-
75th percentiles). Univariate comparisons of risk factors
and other dichotomous variables between the two study
groups were calculated with Fisher exact tests, and contin-
uous variables were evaluated with the nonparametric
Mann-Whitney U test (respective P values were not ad-
justed for multiple comparisons and are therefore only
descriptive). Hardy-Weinberg equilibrium for all three
polymorphisms was tested for by the 2 test with 1 df
separately in cases and controls. The 2 test was also used
for comparing the distributions of the factor V G1691A,
prothrombin G20210A, and MTHFR C677T mutations
in cases and controls. To determine univariate and multi-
variate odds ratios for PAD, logistic regression analysis was
performed; polymorphisms were coded with a dummy
variable of 1 for having the homozygous or heterozygous
condition and 0 for being wild type. Probabilities are 2
tailed, and P  .05 is regarded as statistically significant.
RESULTS
Patients with PAD included in this study (n  433)
were admitted because of mild to severe claudication or leg
pain on exertion (n  359), ischemic rest pain (n  15),
andminor ormajor tissue loss (n 59). Of the 433 patients
with PAD, 131 (30%) had concomitant CAD, and 80
(18%) had concomitant CVD. Furthermore, 101 patients
with PAD had 50% or greater internal carotid stenosis.
Another 18 patients with PAD were classified as having a
stenosis 50% or greater as well, because they had undergone
previous carotid surgery to treat stenosis. At enrollment,
116 patients with PAD had undergone remote percutane-
ous transluminal angioplasty with or without stenting, 86
PAD patients had undergone vascular surgery, and 22
patients with PAD had undergone minor or major ampu-
tations. Of the 318 nondiabetic patients with PAD, 273
(86%) had an ABI of 0.90 or less, and 45 (14%) had an ABI
greater than 0.90; of the 115 diabetic patients with PAD,
94 (82%) had an ABI of 0.90 or less, and 21 (18%) had an
ABI greater than 0.90. Per definition, none of the 433
control subjects matched to the patients with PAD for sex,
age (2 years), and diabetes mellitus had either CAD and
CVD or an internal carotid stenosis 50% or greater. How-
ever, many control subjects (n  365) had carotid plaques
tinenc
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sis. At enrollment, of the patients with PAD, 102 were
receiving a lipid-lowering medication, 10 took a folate
supplement, and 18 took B vitamins (usually in combina-
tion); none of the control subjects took any of these med-
ications. The clinical and biochemical characteristics of all
individuals included in the study are described in Table I.
After enrollment into the study and as a consequence of
the clinical evaluation, the therapy for the 433 patients with
symptomatic PAD was vascular surgery, including open
revascularization procedures or bypass graft placement, in
88 patients; endovascular techniques, such as percutaneous
transluminal angioplasty with or without stenting, in 164
patients; lumbar sympathectomy in 4 patients; major am-
putation in 1 patient; minor amputation in 6 patients;
vascular surgery plus endovascular techniques in 14 pa-
tients; vascular surgery plus minor amputation in 3 patients;
vascular surgery plus endovascular techniques plus lumbar
sympathectomy in 1 patient; vascular surgery plus lumbar
sympathectomy in 1 patient; endovascular techniques plus
minor amputation in 2 patients; endovascular techniques
plus lumbar sympathectomy in 1 patient; and minor ampu-
tation plus lumbar sympathectomy in 1 patient. Also, 147
Table I. Clinical and biochemical data of patients with PA
Variable PAD group (n  4
Male/female (n) 306/127
Age (y) 68 (59-75)
BMI (kg/m2) 26 (24-29)
Current smoking (n)‡ 193
Arterial hypertension (n) 251
Diabetes mellitus (n) 115
CAD (n) 131
CVD (n) 80
Carotid stenosis 50% (n) 119
PAD relevant data
Previous PTA/stenting (n) 116
Previous vascular surgery (n) 86
Previous amputation (n) 22
ABI (mm Hg/mm Hg) 0.63 (0.47-0.79
Biochemical markers
Creatinine (mg/dL) 1.0 (0.9-1.1)
Total cholesterol (mg/dL) 229 (195-258)
LDL cholesterol (mg/dL) 150 (121-178)
HDL cholesterol (mg/dL) 50 (39-61)
Triglycerides (mg/dL) 132 (99-201)
Fasting glucose (mg/dL)§ 96 (88-104)
HbA1c (%)
§ 5.8 (5.5-6.2)
hs-CRP (mg/L) 4.1 (1.8-9.2)
tHcy (mol/L) 16.0 (13.0-21.1
Folate (ng/mL) 7.0 (5.1-9.1)
Vitamin B12 (pg/mL) 341 (245-474)
ABI, Resting ankle-brachial index; BMI, body mass index; CAD, coronary a
high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, l
percutaneous transluminal angioplasty; tHcy, total homocysteine.
Age, BMI, ABI, and biochemical markers are presented as median (25th-75
*Nonparametric Mann-Whitney U test or Fisher exact test as appropriate.
†Matched variables.
‡Current smoking was defined as any amount of tobacco use, including abs
§Subjects with diabetes mellitus were excluded.PAD patients received conservative treatment only (eg,because of no indication for revascularization procedures,
missing patient consent to perform revascularization pro-
cedures, or impossibility to perform revascularization pro-
cedures because of comorbidity).
Genotyping for factor V G1691A, prothrombin
G20210A, and MTHFR C677T polymorphisms was per-
formed successfully in 100% of the study subjects. The
distributions of all three genotypes of the overall study
population (cases, n 433; controls, n 433) are depicted
in Table II and were in Hardy-Weinberg equilibrium (fac-
tor V G1691A in cases: frequency of allele G, 0.964;
frequency of allele A, 0.036; 2  0.597; P  .200; factor
V G1691A in controls: frequency of allele G, 0.970; fre-
quency of allele A, 0.030; 2 0.415; P .200; prothrom-
bin G20210A in cases: frequency of allele G, 0.982; fre-
quency of allele A, 0.018; 2  0.153; P  .200;
prothrombin G20210A in controls: frequency of allele G,
0.986; frequency of allele A, 0.014; 2 0.085; P .200;
MTHFR C677T in cases: frequency of allele C, 0.695;
frequency of allele T, 0.305; 2  0.258; P  .200;
MTHFR C677T in controls: frequency of allele C, 0.693;
frequency of allele T, 0.307; 2  0.327; P  .200). As
shown in Tables III and IV, we additionally assessed the
d control subjects
Control group (n  433) P value*
306/127 0.999†
68 (60-75) .692†
26 (24-29) .211
51 .001
178 .001
115 0.999†
0 NA
0 NA
0 NA
0 NA
0 NA
0 NA
1.18 (1.09-1.29) NA
0.9 (0.8-1.0) .001
215 (182-243) .001
136 (108-158) .001
52 (42-62) .057
117 (88-160) .001
93 (86-102) .003
5.7 (5.4-5.9) .001
2.1 (0.9-6.0) .001
14.3 (11.9-18.0) .001
7.2 (5.4-9.6) .125
349 (254-495) .556
isease; CVD, cerebrovascular disease;HbA1c, glycohemoglobin A1c;HDL,
nsity lipoprotein;NA, not applicable; PAD, peripheral arterial disease; PTA,
rcentiles).
e less than 1 year. 19D an
33)
)
)
rtery d
ow-de
th pedistribution of the three genotypes in different subgroups
%)
%)
)
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patients 75 years of age). Neither in the entire study
population nor in the subgroup analyses was there a signif-
icant difference between cases and controls with respect to
the distribution of factor V G1691A, prothrombin
G20210A, and MTHFR C677T genotypes as tested by 2
test. Accordingly, no significant odds ratios (assessed by
logistic regression analysis) for heterozygous or homozy-
gous genotypes of the three polymorphisms could be ob-
served in the population studied (Tables II-V). Given the
Table II. Overall genotype frequencies in patients with PA
Polymorphism Genotype
All cases
n  433 (100%)
All contr
n  433 (1
GG 402 (92.8%) 407 (94.
Factor V G1691A GA 31 (7.2%) 26 (6.0
AA 0 (0%) 0 (0%)
GG 417 (96.3%) 421 (97.
Prothrombin G20210A GA 16 (3.7%) 12 (2.8
AA 0 (0%) 0 (0%)
CC 207 (47.8%) 204 (47.
MTHFR C677T CT 188 (43.4%) 191 (44.
TT 38 (8.8%) 38 (8.8
Table III. Genotype frequencies in patients with PAD 7
Polymorphism Genotype
Cases
n  331 (100%)
Contro
n  331 (1
GG 307 (92.7%) 311 (90.
Factor V G1691A GA 24 (7.3%) 20 (6.0
AA 0 (0%) 0 (0%)
GG 317 (95.8%) 322 (97.
Prothrombin G20210A GA 14 (4.2%) 9 (2.7
AA 0 (0%) 0 (0%)
CC 157 (47.4%) 156 (47.
MTHFR C677T CT 142 (42.9%) 146 (44.
TT 32 (9.7%) 29 (8.8
Table IV. Genotype frequencies in patients with PAD 7
Polymorphism Genotype
Cases
n  102 (100%)
Contro
n  102 (1
GG 95 (93.1%) 96 (94.1
Factor V G1691A GA 7 (6.9%) 6 (5.9%
AA 0 (0%) 0 (0%)
GG 100 (98.0%) 99 (97.1
Prothrombin G20210A GA 2 (2.0%) 3 (2.9%
AA 0 (0%) 0 (0%)
CC 50 (49.0%) 48 (47.1
MTHFR C677T CT 46 (45.1%) 45 (44.1
TT 6 (5.9%) 9 (8.8%distribution of the factor V G1691A and prothrombinG20210A mutations determined in the entire study popu-
lation, sample-size calculations showed that approximately
8000 cases and controls would have been necessary to
reveal a statistically significant difference of the prevalence
in cases and controls. On the basis of the prevalence of the
MTHFR C677T polymorphism in our study population,
another sample-size calculation indicated that more than
50,000 cases and controls would have been necessary to
obtain a statistically significantly different distribution of
heterozygote and homozygote genotypes for this mutation
nd matched control subjects
2 (P-value) Univariate odds ratios (95% CI; p-value)
1.000
0.469 (P  .493) 1.207 (95%CI,0.704to2.070;p  .494)
—
1.000
0.591 (P  .442) 1.346 (95%CI,0.629to2.880;p  .444)
—
1.000
0.046 (P  .977) 0.970 (95%CI,0.734to1.282;p  .831)
0.986 (95%CI,0.604to1.608;p  .986)
ars of age and matched control subjects
2 (P-value) Univariate odds ratios (95% CI; p-value)
1.000
0.390 (P  .640) 1.126 (95%CI,0.658to2.246;p  .533)
—
1.000
1.126 (P  .396) 1.580 (95%CI,0.674to3.703;p  .292)
—
1.000
0.206 (P  .902) 0.966 (95%CI,0.702to1.331;p  .834)
1.096 (95%CI,0.633to1.899;p  .743)
ars of age and matched control subjects
2 (P-value) Univariate odds ratios (95% CI; p-value)
1.000
0.082 (P  .774) 1.179 (95%CI,0.382to3.638;p  .775)
—
1.000
0.205 (P  .651) 0.660 (95%CI,0.108to4.036;p  .653)
—
1.000
0.652 (P  .722) 0.981 (95%CI,0.555to1.737;p  .948)
0.640 (95%CI,0.212to1.935;p  .429)D a
ols
00%)
0%)
%)
2%)
%)
1%)
1%)5 ye
ls
00%)
4%)
%)
3%)
%)
1%)
1%)5 ye
ls
00%)
%)
)
%)
)
%)
%)in cases and controls. The Figure details the association
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cases and controls.
DISCUSSION
The results of the LIPAD study showed that athero-
sclerotic PAD was not associated with an increased preva-
lence of factor V G1691A, prothrombin G20210A, and
MTHFR C677T mutations. Thus, considering our sample
size calculations, there is no indication that one of these
mutations may be a clinically relevant risk factor for chronic
ischemia of the lower limbs. The prevalence of the three
mutations in both cases and controls was similar to the
prevalence described in previous epidemiologic reports on
white populations.16
As detailed previously, the factor V G1691A and pro-
Table V. Multivariate odds ratios of PAD for factor V
G1691A, prothrombin G20210A, and MTHFR C677T
mutations (433 patients with PAD vs 433 control
subjects)
Risk factor
Multivariate odds
ratios of PAD*
P
value
Current smoking (vs not)† 7.76 (5.24-11.48) .001
Arterial hypertension (vs
not) 2.81 (2.03-3.90) .001
Creatinine (median value
of 0.9 mg/dL) 1.80 (1.27-2.54) .001
LDL cholesterol (median
value of 142 mg/
dL) 1.90 (1.39-2.61) .001
Triglycerides (median
value of 126 mg/
dL) 1.05 (0.76-1.44) .767
hs-CRP (median value of
3.2 mg/L) 1.88 (1.34-2.56) .001
tHcy (median value of
15.0 mol/L) 1.68 (1.22-2.31) .001
Factor V G1691A
polymorphism
GG genotype 1.00
GA genotype 1.26 (0.67-2.36) .472
Prothrombin G20210A
polymorphism
GG genotype 1.00
GA genotype 1.47 (0.62-3.49) .379
MTHFR C677T
polymorphism
CC genotype 1.00
CT genotype 0.98 (0.71-1.35) .885
TT genotype 0.85 (0.48-1.51) .581
Statistical model with continuous variables dichotomized according to the
median values of the entire study population (n  866).
hs-CRP, High-sensitivity C-reactive protein; LDL, low-density lipoprotein;
PAD, peripheral arterial disease; tHcy, total homocysteine; MTHFR, meth-
ylenetetrahydrofolate reductase.
*Data are expressed as odds ratio (95% confidence internal); multivariate
odds ratios were calculated with logistic regression analysis without variable
selection techique (all variables were included simultaneously into the
model). Inasmuch as patient and control groups were matched for age, sex
and diabetes mellitus, these variables were not included into the analysis.
†Current smoking was defined as any amount of tobacco use, including
abstinence less than one year.19thrombin G20210A mutations are widely accepted as riskfactors for the development of venous thromboembo-
lism.15 Their role in arterial thrombotic disease and athero-
sclerosis, however, is controversial,19 and the association of
the factor V G1691A and prothrombin G20210A poly-
Box-and-whisker plots for total serum homocysteine in patients
with peripheral arterial disease (PAD; n  433) and control
subjects (n  433) according to their methylenetetrahydrofolate
reductase (MTHFR) C677T genotype. In box-and-whisker plots,
the central box represents values from the lower to upper quartile,
and the middle line represents the median; whiskers extend from
the minimum to the maximum value, excluding outside (1.5 box
lengths from box) and far-out (3 box lengths from box) values,
which are displayed as open circles and stars, respectively. Median
total homocysteine (25th-75th percentile) values according to the
MTHFR C677T genotype in control subjects were 13.8 mol/L
(11.6-17.3 mol/L) in CC (normal homozygotes  wild type),
14.8 mol/L (12.0-18.2 mol/L) in CT (mutant heterozy-
gotes), and 14.8 mol/L (12.4-19.4 mol/L) in TT (mutant
homozygotes); in patients with PAD, they were 15.6 mol/L
(12.6-19.7mol/L) in CC, 16.0mol/L (13.1-21.7mol/L) in
CT, and 19.2 mol/L (13.9-24.9 mol/L) in TT.morphisms with PAD is even less well characterized. Four
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G1691A mutation is associated with PAD have been pub-
lished.6-9 The two earlier studies suggested that the factor
V G1691A mutation may be a risk factor for PAD,6,7 but
the two studies published more recently did not find such
evidence.8,9 The prothrombin G20210A polymorphism
has been evaluated as a risk factor of PAD by two published
studies that also found conflicting results.8,9 Only one
study indicated a significant association between PAD and
the prothrombin G20210A mutation. The studies investi-
gating the association of PAD with hyperhomocysteinemia
and the MTHFR C677T polymorphism are raising doubts
about the putative causal relationship between the
MTHFR C677T mutation and PAD.10-15 These six stud-
ies, similar to the studies on factor V G1691A and pro-
thrombin G20210A polymorphisms, differ considerably in
size and in the selection of patients and controls. In addi-
tion, as indicated in the introduction, some of these studies
did not provide an appropriate spectrum or delineation of
cases and controls.19 As a consequence, on the basis of
these publications, a definite statement related to the asso-
ciation of PAD with factor V G1691A, prothrombin
G20210A, and MTHFR C677T polymorphisms has not
been possible until now.
The pathogenesis of arterial thrombotic disease is com-
plex and involves multiple genetic and environmental fac-
tors related to atherosclerosis and thrombosis, as well as
their interaction.27 Classically, acute thrombosis at the site
of a ruptured, lipid-rich atherosclerotic plaque is under-
stood as the precipitating event in the transition from stable
or subclinical atherosclerotic disease to acute myocardial
infarction or stroke.28 Similar mechanisms resulting in pe-
ripheral arterial thrombosis are considered causative for
acute ischemia of the lower limbs.28 Conversely, chronic
ischemia of the lower limbs is the consequence of the
progression of atherosclerosis with the occurrence of he-
modynamically relevant stenoses and occlusions of the ar-
terial tree, but without clinically relevant thromboembolic
events.29,30 Although atherosclerosis is pathologically a
continuously progressive disease (assuming that the pro-
moting factors continue unabated), the clinical pattern in
PAD consists of episodes of deterioration followed by
resolution with long periods of stability or apparent im-
provement due to compensatory mechanisms—particularly
the development of collateral circulatory pathways around
obstructed segments.31
These differences in the natural history of acute isch-
emia and chronic ischemia in patients with PAD may be
related to distinct risk profiles including specific genes that
may be responsible for the occurrence of thrombotic
events. The current evidence supports the hypothesis that
factor V G1691A, prothrombin G20210A, and MTHFR
C677T mutations may be a risk factor for acute arterial
occlusive events, including myocardial infarction and
stroke, by modest but significant associations.19 Assuming
thrombophilic conditions, similar associations may also
hold true for acute ischemic events in PAD patients (eg,
peripheral arterial thrombosis of a native artery or poplitealartery aneurysm; thrombosed peripheral bypass grafts; or
cardioembolic disease). This would be in accordance with
observations in smaller populations that peripheral bypass
graft thrombosis may be related to one of these three
mutations.7,32-34 However, considering the natural history
of chronic ischemia of the lower limbs, as detailed previ-
ously, there is no rationale for premising that a thrombo-
philic state caused by a factor V G1691A, prothrombin
G20210A, or MTHFR C677T mutation should be associ-
ated with PAD. Accordingly, the results of the LIPAD
study, demonstrating no relationship of chronic ischemia of
the lower limbs and the three polymorphisms, are conclu-
sive. These considerations may, at least in part, explain the
conflicting results on factor V G1691A, prothrombin
G20210A, and MTHFR C677T mutations in previous
studies as potential risk factors for PAD, as described pre-
viously, because these studies obviously included patients
with both acute and chronic ischemia of the lower limbs
and thus possibly included different proportions of these
two disease states.
The LIPAD study included a series of 487 consecutive
patients with symptomatic PAD. However, matched con-
trols were recruited only for nondiabetic patients and for
those with diabetes mellitus but who were younger than 75
years of age (n 433). This may be considered a limitation,
but given our very stringent study design, it may have been
impossible to enroll the required 54 diabetic controls 75
years of age or older without any relevant atherosclerotic
manifestation, as detailed in the Methods section. Another
limitation of this study may be that the study population
was a selected subgroup of the overall population of PAD,
as described in the Methods section (white patients admit-
ted for inpatient diagnostics and treatment of atheroscle-
rotic PAD). Thus, the findings cannot be generalized to
non-Caucasian patients, asymptomatic patients with PAD,
or patients who do not meet criteria for hospitalization.
However, if there were an association between PAD and
thrombophilic risk factors, this would be expected to be
most easily detected in the most severely diseased patients
(ie, the symptomatic patients admitted to the hospital).
Thus, although the findings of the LIPAD study may not
be generalizable, we probably did not miss a significant
association.
In conclusion, the LIPAD study demonstrated that
PAD was not associated with an increased prevalence of the
factor V G1691A, prothrombin G20210A, and MTHFR
C677T mutations. Thus, considering the natural history of
chronic ischemia of the lower limbs, there is no indication
that one of these mutations may be a risk factor for chronic
limb ischemia. Accordingly, routine screening for factor V
G1691A, prothrombin G20210A, and MTHFR C677T
mutations is not justified in this patient group, in our
opinion. However, the role of these mutations in acute
limb ischemia remains to be clarified by further studies.
REFERENCES
1. Hiatt WR. Medical treatment of peripheral arterial disease and claudi-
cation. N Engl J Med 2001;344:1608-21.
JOURNAL OF VASCULAR SURGERY
Volume 41, Number 5 Mueller et al 8152. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et
al. Critical issues in peripheral arterial disease detection and manage-
ment: a call to action. Arch Intern Med 2003;163:884-92.
3. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology
of peripheral arterial disease: importance of identifying the population at
risk. Vasc Med 1997;2:221-6.
4. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk
prediction. J Intern Med 2002;252:283-94.
5. Mueller T, Dieplinger B, Gegenhuber A, Haidinger D, Schmid N, Roth
N, et al. Serum total 8-iso-prostaglandin F2alpha: a new and indepen-
dent predictor of peripheral arterial disease. J Vasc Surg 2004;40:768-
73.
6. Foley PW, Irvine CD, Standen GR, Morse C, Smith FT, McGrath C, et
al. Activated protein C resistance, factor V Leiden and peripheral
vascular disease. Cardiovasc Surg 1997;5:157-60.
7. Sampram ES, Lindblad B, Dahlback B. Activated protein C resistance in
patients with peripheral vascular disease. J Vasc Surg 1998;28:624-9.
8. RennerW, Koppel H, BrodmannM, Pabst E, Schallmoser K, ToplakH,
et al. Factor II G20210A and factor V G1691A gene mutations and
peripheral arterial occlusive disease. Thromb Haemost 2000;83:20-2.
9. Reny JL, Alhenc-GelasM, Fontana P, Bissery A, Julia PL, Fiessinger JN,
et al. The factor II G20210A gene polymorphism, but not factor V
Arg506Gln, is associated with peripheral arterial disease: results of a
case-control study. J Thromb Haemost 2004;2:1334-40.
10. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJ, Reitsma PH. The effect
of a common methylenetetrahydrofolate reductase mutation on levels
of homocysteine, folate, vitamin B12 and on the risk of premature
atherosclerosis. Atherosclerosis 1998;141:161-6.
11. Todesco L, Angst C, Litynski P, Loehrer F, Fowler B, Haefeli WE.
Methylenetetrahydrofolate reductase polymorphism, plasma homocys-
teine and age. Eur J Clin Invest 1999;29:1003-9.
12. Rassoul F, Richter V, Janke C, Purschwitz K, Klotzer B, Geisel J, et al.
Plasma homocysteine and lipoprotein profile in patients with peripheral
arterial occlusive disease. Angiology 2000;51:189-96.
13. Fowkes FG, Lee AJ, Hau CM, Cooke A, Connor JM, Lowe GD.
Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide syn-
thase (ecNOS) genes and risks of peripheral arterial disease and coro-
nary heart disease: Edinburgh Artery Study. Atherosclerosis 2000;150:
179-85.
14. Stricker H, Soldati G, Balmelli T, Mombelli G. Homocysteine, vitamins
and gene mutations in peripheral arterial disease. Blood Coagul Fibri-
nolysis 2001;12:469-75.
15. Ciccarone E, Di Castelnuovo A, Assanelli D, Archetti S, Ruggeri G,
Salcuni N, et al. Homocysteine levels are associated with the severity of
peripheral arterial disease in Type 2 diabetic patients. J Thromb Hae-
most 2003;1:2540-7.
16. Crowther MA, Kelton JG. Congenital thrombophilic states associated
with venous thrombosis: a qualitative overview and proposed classifica-
tion system. Ann Intern Med 2003;138:128-34.
17. Bauer KA, Rosendaal FR, Heit JA. Hypercoagulability: too many tests,
too much conflicting data. Hematology 2002;353-68.
18. Key NS, McGlennen RC. Hyperhomocyst(e)inemia and thrombo-
philia. Arch Pathol Lab Med 2002;126:1367-75.
19. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin
G20210A, and methylenetetrahydrofolate reductase C677T mutationsand events of the arterial circulatory system: ameta-analysis of published
studies. Am Heart J 2003;146:948-57.
20. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
21. Sacks D, Bakal CW, Beatty PT, Becker GJ, Cardella JF, Raabe RD, et al.
Position statement on the use of the ankle brachial index in the
evaluation of patients with peripheral vascular disease. J Vasc Interv
Radiol 2003;14:S389.
22. Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth
EI, et al. Carotid artery stenosis: gray-scale andDoppler US diagnosis—
Society of Radiologists in Ultrasound Consensus Conference. Radiol-
ogy 2003;229:340-6.
23. Lay MJ, Wittwer CT. Real-time fluorescence genotyping of factor V
Leiden during rapid-cycle PCR. Clin Chem 1997;43:2262-7.
24. von Ahsen N, Schutz E, Armstrong VW, Oellerich M. Rapid detection
of prothrombotic mutations of prothrombin (G20210A), factor V
(G1691A), and methylenetetrahydrofolate reductase (C677T) by real-
time fluorescence PCR with the LightCycler. Clin Chem 1999;45:
694-6.
25. Bernard PS, Lay MJ, Wittwer CT. Integrated amplification and detec-
tion of the C677T point mutation in the methylenetetrahydrofolate
reductase gene by fluorescence resonance energy transfer and probe
melting curves. Anal Biochem 1998;255:101-7.
26. Endler G, Kyrle PA, Eichinger S, Exner M, Mannhalter C. Multiplexed
mutagenically separated PCR: simultaneous single-tube detection of
the factor V R506Q (G1691A), the prothrombin G20210A, and the
methylenetetrahydrofolate reductase A223V (C677T) variants. Clin
Chem 2001;47:333-5.
27. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis.
Arterioscler Thromb Vasc Biol 2004;24:216-29.
28. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;
340:115-26.
29. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR. Large
vessel and isolated small vessel disease. In: Fowkes FGR, editor. Epide-
miology of peripheral vascular disease. New York: Springer-Verlag;
1991. p. 85-96.
30. Mohler ER III. Peripheral arterial disease: identification and implica-
tions. Arch Intern Med 2003;163:2306-14.
31. Ruckley CV. Symptomatic and asymptomatic disease. In: Fowkes FGR,
editor. Epidemiology of peripheral vascular disease. New York: Spring-
er-Verlag; 1991. p. 97-108.
32. Ouriel K, Green RM, DeWeese JA, Cimino C. Activated protein C
resistance: prevalence and implications in peripheral vascular disease. J
Vasc Surg 1996;23:46-51.
33. Sampram ES, Lindblad B. The impact of factor V mutation on the risk
for occlusion in patients undergoing peripheral vascular reconstruc-
tions. Eur J Vasc Endovasc Surg 2001;22:134-8.
34. Kibbe MR, Hassett AL, McSherry F, Conner P, Bontempo FA, Willi-
ford W, et al. Can screening for genetic markers improve peripheral
artery bypass patency? J Vasc Surg 2002;36:1198-206.Submitted Dec 22, 2004; accepted Jan 22, 2005.
